摘要
目的:观察适丽顺(卵磷脂络合碘胶囊)治疗视网膜中央静脉阻塞有效性和安全性。方法回顾性分析84例84眼视网膜中央静脉阻塞患者的临床资料,应用适丽顺联合维脑路通口服作为治疗组,对照组仅给予维脑路通口服,并加强对高血压和糖尿病等原发病的治疗。其中43例缺血型视网膜中央静脉阻塞,在用药的过程中给予全视网膜规范光凝术治疗,其余41例为非缺血型视网膜中央静脉阻塞;3个月后观察两组不同类型的视网膜中央静脉阻塞眼底出血吸收情况,黄斑水肿恢复情况,视力提高情况,血常规和肝肾功情况。结果眼底出血吸收情况为研究组有效率为84.4%,对照组为62.5%,研究组的有效率高于对照组(P<0.01);研究组视力提高率为78.1%,对照组为53.6%,研究组视力提高疗效优于对照组(P<0.01)。血常规及肝肾功未见异常。结论适丽顺治疗视网膜中央静脉阻塞可加快视网膜静脉阻塞患者的眼底出血吸收时间和提高患者视力,减少黄斑水肿的发生率,临床应用安全性好,值得临床广泛推广应用。
Objective To observe the Safety and ef ectiveness of using Shilishun(iodized lecithin capsules)for treatment of central retinal vein occlusion.Methods A retrospective analysis of the clinical data of 84 patients 84 eyes with central retinal vein occlusion,application of Shilishun Joint Venoruton oral as treatment group,the control group was given Venoruton oral,and strengthen the treatment for primary disease,such as hypertension and diabetes and so on.Among the 43 cases of ischemic central retinal vein occlusion,given photocoagulation for treatment of retinal specification in the medication process,the remaining 41 cases of non ischemic central retinal vein occlusion;3 months after the observation of the two groups of dif erent types of central retinal vein occlusion fundus hemorrhage,macular edema recovery,visual acuity improvement,blood routine and liver and kidney function status.Results Retinal hemorrhage absorption:as the study group was 84.4%(54/43),the control group was 62.5%(35/11),the ef ective rate of study group was higher than that of the control group(<0.01);the study group vision improvement rate was 78.1%(50/43),the control group was 53.6%(30/41),vision improvement of the research group was bet er than the control group(<0.01).Blood routine and liver and kidney function was normal.Conclusion It can accelerate the absorption of retinal hemorrhage time and improve the visual acuity of using Shilishun to treat the central retinal vein occlusion,reduce the incidence of cystoid macular edema,and can reduce the non ischemic RVO into ischemic,clinical application security is good,worthy of clinical popularization and application.
作者
解孝锋
毕宏生
王兴荣
潘雪梅
刘婷婷
韩冠宇
XIE Xiao-feng;BI Hong-sheng;WANG Xing-rong;PAN Xue-mei;LIU Ting-ting;HAN Guan-yu(The Affiliated Ophthalmology Hospital of Shandong University of Traditional Chinese Medicine/Shandong Shierming Ophthalmology Hospital,Jinan 250000,Shandong,China)
